Special Interest Group Programming

Interested in a specialized area of hepatology? Join TLMdX's SIG sessions to exchange ideas with experts on trending topics. Sessions include:

Paving the Road to Hepatitis C Elimination | Hepatitis C SIG

This program will summarize key concepts in U.S. and global strategies to achieve hepatitis C elimination. Experts will address topics such as new universal screening recommendations, novel paradigms for care delivery beyond the specialty clinic, global strategies for microelimination, treatment as prevention in persons who inject drugs (PWID), and the latest updates on HCV vaccine development.

Learning Objectives:

• Review emerging strategies for U.S. and global HCV microelimination through adoption of universal screening and novel paradigms for care delivery.
• Discuss emerging evidence and approaches to treatment as prevention for HCV in persons who inject drugs (PWID.)
• Discuss updates in the development of an effective HCV vaccine.

Hot Topics in the Pathogenesis and Treatment of Liver Cancer (HCC and iCCA) | Hepatobiliary Neoplasia SIG & Liver Transplantation and Surgery SIG (Part 2)

This engaging session will explore hot topics in the management of liver cancer, including talks on hepatobiliary neoplasia and liver transplant. The program’s first segment will address advancements in research on the pathogenesis and surgical management of liver cancer, while the second half provides analysis of the newest advances in the systemic management of both iCCA and HCC.

Learning Objectives:

• Review the advancements in the knowledge of the pathogenesis of the liver cancer.
• To update the information on management of ICCA and ICC, surgical, loco-regional and systemic treatment.
• To understand advancements in trial design for HCC.
• To understand the role of immunotherapy in the management of ICC and HCC.

NASH Fibrosis: From Matrix to Medicine | Liver Fibrosis SIG

This SIG reveals recent progress made in liver fibrosis related to NASH, including new molecular mechanisms and translational aspects of NASH-mediated fibrosis and cirrhosis, and translation of laboratory findings into humans. Speakers will cover significant new information about the potential role of hepatocytes, crosstalk with non-parenchymal cells in NASH-fibrosis, and potential non-invasive biomarkers and treatments of patients with NASH-fibrosis.

Learning Objectives:

• Describe the molecular mechanisms of NASH-fibrosis and the contribution of hepatocytes and their crosstalk with non-parenchymal cells in the development of NASH-fibrosis.
• Discuss how basic science discoveries may be translated to new non-invasive biomarkers and therapeutics for NASH-fibrosis.
• Explain how basic science discoveries may be translated to new non-invasive biomarkers and therapeutics for NASH-fibrosis.

Controversies in the Diagnosis and Management of Non-cirrhotic Portal Hypertension in Children and Adults | Pediatric Liver Disorders SIG & Portal Hypertension SIG (Part 1)

This two-session program explores non-cirrhotic portal hypertension in both children and adults. The first session covers the definition/nomenclature and diagnostic strategies for non-cirrhotic portal hypertension. The second session explores monitoring and management of children and adults with non-cirrhotic portal hypertension, including medical, interventional radiology and surgical challenges. Each session includes case presentations to highlight controversies, expert panel interviews and Q&A.

Learning Objectives:

• Review the definition, nomenclature and diagnostic approach for non-cirrhotic portal hypertension.
• Review the similarities and differences in the etiology of non-cirrhotic portal hypertension in pediatric and adult populations.
• Discuss the indications for treatment strategies, including medical, radiologic and surgical intervention of non-cirrhotic portal hypertension in children and adults.

Clinical Unmet Needs in Alcohol-associated Liver Disease (ALD)

Alcohol-associated liver disease (ALD) has emerged as a leading indicator of liver disease and the need for organ transplant. Currently, we lack effective pharmacological therapies to improve long-term outcomes in ALD patients, but new research advances are highly encouraging. Join this ALD SIG program for important research updates and to identify unmet clinical needs in ALD patients.

Learning Objectives:

• Discuss the latest research developments in alcohol-associated liver disease.
• Recognize unmet clinical needs in alcohol-associated liver disease.
• Compose take-home points for better care of ALD patients and ideas for future research.

‍